Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update

References

• International Diabetes Federation 2009 http://www.idf.org/ Accessed December 10, 2009
   Google Scholar
• World Health Organization 2009 http://www.who.int/diabetes/facts/world_figures/en/ Accessed December 10, 2009
   Google Scholar
• Levy J Atkinson AB Bell PM McCance DR Hadden DR Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study Diabet Med 1998 15 290 296 9585393
   PubMed Web of Science ®Google Scholar
• Rudenski AS Hadden DR Atkinson AB Natural history of pancreatic islet B-cell function in type 2 diabetes mellitus studied over six years by homeostasis model assessment Diabet Med 1988 5 36 41 2964326
   PubMed Web of Science ®Google Scholar
• Mitrakou A Kelley D Venerman T Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycaemia in NIDDM Diabetes 1990 39 1381 1390 2121568
   PubMed Web of Science ®Google Scholar
• Stratton IM Adler AI Neil HAW on behalf of the UK Prospective Diabetes Study Group Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 2000 321 405 412 10938048
   PubMed Web of Science ®Google Scholar
• Haffner SM Lehto S Rönnemaa T Pyörälä K Laakso M Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 1998 339 229 234 9673301
   PubMed Web of Science ®Google Scholar
• Nathan DM Buse JB Davidson MB Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy Diabetes Care 2009 32 193 203 18945920
   PubMed Web of Science ®Google Scholar
• Rodbard HW Davidson JA Garber AJ Handelsman Y Lebovitz H Moghissi ES Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control Endocr Pract 2009 15 540 559 19858063
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Standards of medical care in diabetes – 2009 Diabetes Care 2009 32 Suppl 1 S13 S61 19118286
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation Guideline for management of postmeal glucose Brussels International Diabetes Federation 2007 http://www.idf.org/guideline_postmeal Accessed December 10, 2009
   Google Scholar
• Moses R Slobodniuk R Boyages S Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes Diabetes Care 1999 22 119 124 10333912
   PubMed Web of Science ®Google Scholar
• Melikian C White TJ Vanderplas A Dezii CM Chang E Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy Clin Ther 2002 24 460 467 11952029
   PubMed Web of Science ®Google Scholar
• Blonde L Wogen J Kreilick C Seymour AA Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin Diabetes Obes Metab 2003 5 424 431 14617228
   PubMed Web of Science ®Google Scholar
• Novo Nordisk Inc Prescribing information for PrandiMet (repaglinide and metformin HCl) tablets 2008 www.prandimet.com Accessed December 10, 2009
   Google Scholar
• Moses R Fixed combination of repaglinide and metformin in the management of type 2 diabetes Diabetes Metab Syndr Obes 2009 2 101 109
   Google Scholar
• Sambol NC Brookes LG Chiang J Food intake and dosage level, but not tablet vs solution dosage form, affect the absorption of metformin HCl in man Br J Clin Pharmacol 1996 42 510 512 8904626
   PubMed Web of Science ®Google Scholar
• Hoelscher D Chu PL Lyness W Fixed-dose combination tablet of repaglinide and metformin is bioequivalent to concomitantly administered individual tablets of repaglinide and metformin Clin Drug Invest 2008 28 573 582
   PubMed Web of Science ®Google Scholar
• Reilley S Chang CT Lyness W Single-dose pharmacokinetics of a repaglinide/metformin fixed-dose combination tablet in fasted and fed conditions Diabetes 2008 57 Suppl 1 A589
   Google Scholar
• Moses R Achieving glycosylated haemoglobin targets using the combination of repaglinide and metformin in type 2 diabetes: a reanalysis of earlier data in terms of current targets Clin Ther 2008 30 552 554 18405794
   PubMed Web of Science ®Google Scholar
• Raskin P Klaff L McGill J for the repaglinide vs nateglinide metformin combination study group Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin Diabetes Care 2003 26 2063 2068 12832314
   PubMed Web of Science ®Google Scholar
• Reboussin DM Goff DC Lipkin EW The combination and nutritional treatment of late-onset diabetes mellitus (CONTROL DM) trial results Diabet Med 2004 21 1082 1089 15384954
   PubMed Web of Science ®Google Scholar
• Raskin P Lewin A Reinhardt R Lyness W for the repaglinide/metformin fixed-dose combination study group Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycemic control Diab Obes Metab 2009 11 947 952
   PubMed Web of Science ®Google Scholar
• Raskin P Lewin A Reinhardt R Lyness W for the repaglinide/metformin fixed-dose combination study group Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycemic control comparable to rosiglitazone/metformin tablet Diab Obes Metab 2009 11 865 873
   PubMed Web of Science ®Google Scholar
• Wolffenbuttel BH Landgraf R A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes Diabetes Care 1999 22 463 467 10097930
   PubMed Web of Science ®Google Scholar
• Marbury T Huang WC Strange P Lebovitz H Repaglinide versus glyburide: a one-year comparison trial Diabetes Res Clin Pract 1999 43 155 166 10369424
   PubMed Web of Science ®Google Scholar
• Derosa G Mugellini A Ciccarelli L Crescenzi G Fogari R Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors Clin Ther 2003 25 472 484 12749508
   PubMed Web of Science ®Google Scholar
• Black C Donnelly P McIntyre L Royle P Shepherd JJ Thomas S Meglitinide analogues for type 2 diabetes mellitus Cochrane Database Syst Rev 2007 Issue 2 Art.No.:CD004654 10.1002/14651858.CD004654.pub2
   Web of Science ®Google Scholar
• Salpeter SR Greyber E Pasternak GA Salpeter EE Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus Cochrane Database Syst Rev 2006 Issue 1 Art. No.: CD002967 10.1002/14651858.CD002967.pub2
   Web of Science ®Google Scholar
• Owens DR Repaglinide – prandial glucose regulator: a new class of oral antidiabetic drug Diabet Med 1998 15 Suppl 4 S28 S36 9868989
   PubMed Web of Science ®Google Scholar
• Saenz A Fernandez-Esteban I Mataix A Ausejo M Roque M Moher D Metformin monotherapy for type 2 diabetes mellitus Cochrane Database Syst Rev 2005 3 CD002966 16034881
   PubMedGoogle Scholar
• Bolen S Feldman L Vassy J Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus Ann Intern Med 2007 147 386 399 17638715
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Co Package insert for Glucophage^® (metformin hydrochloride) tablets and Glucophage^® XR (metformin hydrochloride extended-release) tablets 2009 http://packageinserts.bms.com/pi/pi_glucophage.pdf last accessed December 10, 2009
   Google Scholar
• Schramm TK Gislason G Vaag A Differences in risk of cardiovascular death according to type of oral glucose-lowering therapy in patients with diabetes: a nationwide study Diabetes 2009 58 Suppl 1 A24
   Google Scholar
• Bonneville M Colgin J Nalesnick JA Perez J Wentz L Patient perceptions of prandial oral therapy for type 2 diabetes Diabetes Educ 2001 27 659 677
   Web of Science ®Google Scholar